Testosterone Cypionate Side Effects: Severity Distribution by Patient Phenotype

What the FDA Label Actually Says About Testosterone Cypionate Adverse Events

The FDA-approved prescribing information for testosterone cypionate lists adverse reactions across several organ systems, with a boxed warning specifically for blood clots and polycythemia added following a 2014 FDA safety communication. The label distinguishes between adverse reactions observed in clinical trials and those identified through post-marketing surveillance, a distinction that matters enormously for estimating real-world risk.

The 2014 FDA Drug Safety Communication stated: "We are requiring that the labeling of all approved testosterone products be revised to reflect the possible increased risk of heart attacks and strokes associated with use." That language remains in the current prescribing information [1].

Labeled Adverse Reactions by System

The current Depo-Testosterone label organizes adverse reactions as follows [2]:

• Cardiovascular: hypertension, venous thromboembolism, myocardial infarction (post-marketing)
• Hematologic: erythrocytosis, polycythemia (both trial and post-market)
• Dermatologic: acne, oily skin, injection-site reactions including fibrosis with repeated IM use
• Endocrine/reproductive: suppression of spermatogenesis, testicular atrophy, gynecomastia
• Psychiatric: aggression, mood lability, rarely mania
• Hepatic: peliosis hepatis and hepatic neoplasms (at supraphysiologic doses, largely historic data from oral androgens)
• Genitourinary: BPH exacerbation, increased urinary frequency, PSA elevation

FAERS Signal Strength

The FDA Adverse Event Reporting System (FAERS) contains over 14,000 individual case safety reports for testosterone products through 2023. Polycythemia and pulmonary embolism are the two highest-signal adverse events by proportional reporting ratio when testosterone is compared with all drugs in the database [3]. These are not rare signals buried in noise. They dominate the post-market safety picture.

Mild Adverse Events: Who Gets Them and How Often

Mild adverse events affect the majority of testosterone cypionate users at some point during treatment. In a 2010 randomized trial of 308 hypogonadal men receiving testosterone gel or injection therapy, 62% reported at least one mild adverse event over 12 months, most commonly acne (18%), injection-site discomfort (14%), and increased libido that was personally unwanted (9%) [4].

Injection-Site Reactions

Injection-site pain, induration, and local fibrosis are the most reported mild adverse events. Frequency is higher with IM gluteal injection than with subcutaneous deltoid or abdominal injection. A 2021 pharmacokinetic comparison found that subcutaneous testosterone cypionate at 50-70 mg weekly produced smoother testosterone curves and fewer injection-site complaints than standard IM dosing at 100-200 mg every two weeks [5].

Patients with higher body-mass index (BMI greater than 35) who self-inject into the lateral thigh show the highest rate of post-injection nodule formation, likely due to variable intramuscular depth with standard needle lengths.

Acne and Dermatologic Effects

Acne incidence tracks closely with supraphysiologic peaks. Dosing intervals that create high peak testosterone, such as 200 mg every two weeks, drive greater androgen receptor activation in sebaceous glands than more frequent lower doses achieving identical average serum levels. Adolescent or young adult males (<30 years) and patients with a personal or family history of cystic acne appear to develop acne at roughly twice the rate of men over 45 receiving the same regimen.

Mood and Libido Changes

Mild mood changes, including increased irritability in the first 4-6 weeks of therapy, resolve in most patients once testosterone levels stabilize. Sustained mood disturbance beyond 3 months should prompt serum estradiol measurement, as elevated estradiol secondary to aromatization is a common and correctable driver.

Moderate Adverse Events: Erythrocytosis and Hematologic Risk

Erythrocytosis (hematocrit above 50-54%) is the single most common moderate adverse event and the one that most often forces dose adjustment or therapy discontinuation. It is dose-dependent, cumulative, and strongly phenotype-dependent.

Baseline Predictors of Erythrocytosis

The Endocrine Society's 2018 Clinical Practice Guideline on testosterone therapy states: "We suggest measuring hematocrit before starting testosterone therapy, at 3-6 months, and then annually. If the hematocrit is greater than 54%, stop therapy until the hematocrit decreases to a safe level." [6]

Risk factors for testosterone-induced erythrocytosis include:

• Baseline hematocrit of 48-50% (relative risk approximately 3-fold higher than men starting at 42-44%)
• Altitude of residence above 5,000 feet
• Current tobacco use
• Concurrent use of erythropoiesis-stimulating agents
• IM dosing with two-week intervals (vs. Weekly subcutaneous)

A 2013 meta-analysis of 51 randomized controlled trials (N=4,482) found that testosterone therapy increased hematocrit by a mean of 3.2 percentage points (95% CI 2.5-4.0) and increased the odds of erythrocytosis by 3.69-fold compared with placebo [7].

Time Course of Erythrocytosis

Hematocrit elevation typically begins within 4-6 weeks and reaches a new plateau by months 3-6. Men who do not develop erythrocytosis within the first 6 months at stable doses are unlikely to do so unless the dose is increased. This time window is the most important monitoring period.

Managing Erythrocytosis Without Discontinuing Therapy

Options for managing dose-limiting erythrocytosis include therapeutic phlebotomy, dose reduction, interval shortening (more frequent but smaller injections), or switching from IM to subcutaneous administration. Spontaneous resolution after dose hold typically occurs within 6-10 weeks.

Serious Adverse Events: Cardiovascular, Thromboembolic, and Sleep-Related

Serious adverse events are uncommon in well-selected patients but carry significant morbidity when they occur. Three categories dominate the serious-AE field: cardiovascular events, venous thromboembolism, and sleep apnea exacerbation.

Cardiovascular Risk by Phenotype

The cardiovascular risk data for testosterone therapy are genuinely contested in the literature. Two studies published within months of each other in 2023-2024 illustrate the complexity.

The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, randomized middle-aged and older men with hypogonadism and pre-existing cardiovascular disease or high cardiovascular risk to testosterone gel or placebo for a mean of 33 months. The primary cardiovascular composite (MACE) showed non-inferiority of testosterone vs. Placebo (hazard ratio 0.96, 95% CI 0.78-1.17), but atrial fibrillation (3.5% vs. 2.4%) and acute kidney injury (2.3% vs. 1.5%) were significantly more frequent in the testosterone arm [8].

The critical phenotype lesson from TRAVERSE: men with pre-existing cardiovascular disease did not face a dramatically higher MACE rate on testosterone, but incident atrial fibrillation emerged as a signal that was not anticipated from earlier observational data. Men with pre-existing AF or palpitations warrant ECG monitoring at baseline and 6 months.

Venous Thromboembolism

The FDA boxed warning on testosterone products specifically calls out VTE risk. The mechanism involves both erythrocytosis-driven hyperviscosity and possible direct effects on coagulation factors. A nested case-control analysis using the UK Clinical Practice Research Datalink (N=19,215 men receiving testosterone) found a 63% increased odds of VTE in the first six months of therapy compared with age-matched non-users (adjusted OR 1.63, 95% CI 1.12-2.37) [9].

High-risk VTE phenotypes include:

• Prior VTE history (absolute contraindication in most guidelines)
• Known thrombophilia (Factor V Leiden, Protein C/S deficiency)
• Concurrent hematocrit above 52%
• Immobility greater than 72 hours (post-surgical patients)

Obstructive Sleep Apnea Exacerbation

Testosterone worsens obstructive sleep apnea (OSA) through both central and peripheral mechanisms. Men with moderate-to-severe untreated OSA should not start testosterone therapy until OSA is actively managed, per Endocrine Society guidance [6]. In the TRAVERSE trial, new or worsening sleep apnea occurred in 1.5% of testosterone-treated men vs. 0.8% of placebo-treated men, a statistically significant difference [8].

Men with a BMI above 32, a neck circumference above 17 inches, or a reported history of snoring should undergo formal sleep evaluation before treatment initiation.

Severity Distribution by Patient Phenotype: A Clinical Framework

The table below synthesizes trial data, FAERS signals, and guideline risk stratification into a working clinical framework for severity prediction by phenotype. This framework is not validated in a prospective trial; it is a structured synthesis of current evidence for clinical decision support.

| Phenotype | Most Likely AE | Severity Grade | Monitoring Priority | |---|---|---|---| | Healthy hypogonadal male, age 25-45, BMI <30, no comorbidities | Injection-site reaction, acne, transient libido change | Mild (Grade 1) | Hct, testosterone trough at 3 months | | Male age 45-65, BMI 30-35, dyslipidemia, no prior CVD | Erythrocytosis, mild BP elevation | Mild-to-Moderate (Grade 1-2) | Hct, lipids, BP at 3 and 6 months | | Male age 55+, baseline Hct 48-50%, altitude resident | Erythrocytosis requiring dose adjustment | Moderate (Grade 2) | Hct monthly for first 6 months | | Male with OSA (untreated or on CPAP with residual AHI >15) | Sleep apnea exacerbation | Moderate-to-Severe (Grade 2-3) | Sleep study before initiation; repeat at 3 months | | Male with prior VTE or thrombophilia | Deep vein thrombosis, pulmonary embolism | Severe (Grade 3-4) | Avoid unless hematology consultation obtained | | Male with established CVD, prior AF | Atrial fibrillation, AKI | Moderate-to-Severe (Grade 2-3) | ECG, renal function at baseline and 6 months | | Male with BPH (IPSS score >19) | Urinary retention, worsening LUTS | Moderate (Grade 2) | IPSS and post-void residual at 3 months | | Transgender man on gender-affirming testosterone | Erythrocytosis, lipid shift | Mild-to-Moderate | Hct and lipid panel every 3 months in year 1 |

Grading follows CTCAE version 5.0 conventions, where Grade 1 is asymptomatic/mild, Grade 2 requires non-urgent medical intervention, Grade 3 requires hospitalization or disabling limitation, and Grade 4 is life-threatening [10].

Adverse Events in Women and Gender-Diverse Patients

Women prescribed testosterone cypionate for hypoactive sexual desire disorder (HSDD) or gender-affirming care experience a distinct adverse event profile. Virilization, the development of irreversible masculine characteristics, is the primary moderate-to-severe concern at doses above the physiologic female range.

Irreversible adverse effects in women include clitoral enlargement (typically begins within 3-6 months at doses of 50 mg or more per month), voice deepening (often begins 3-9 months into therapy), and androgenic alopecia. These are Grade 2-3 events by CTCAE criteria and are permanent after onset.

A 2019 systematic review and meta-analysis in The Lancet Diabetes and Endocrinology (N=8 trials, 1,957 women) found that testosterone therapy for HSDD at doses approximating the physiologic female range (targeting serum testosterone of 1.0-2.5 nmol/L) produced no significant increase in serious adverse events over 24 weeks, though acne and increased hair growth were 3-4 times more common than placebo [11].

Erythrocytosis is less common in women receiving testosterone than in men, likely due to lower baseline hematocrit and smaller absolute doses, but hematocrit monitoring at 3 and 6 months is still indicated.

Drug Interactions That Amplify Adverse Event Risk

Certain co-medications predictably worsen the severity distribution of testosterone cypionate adverse events.

Anticoagulants

Testosterone enhances the effects of warfarin by competing for cytochrome P450 binding sites, increasing the international normalized ratio (INR). The FDA label specifies that patients on oral anticoagulants require more frequent INR monitoring when testosterone therapy is initiated or the dose is changed [2]. A dose reduction in warfarin of 10-25% is commonly required.

Insulin and Antidiabetic Agents

Testosterone improves insulin sensitivity, which may cause hypoglycemia in men with type 2 diabetes who are already on sulfonylureas or insulin. The TIMES2 trial demonstrated that testosterone therapy in diabetic hypogonadal men significantly reduced insulin resistance (HOMA-IR change: -1.73 vs. Placebo, P<0.05), requiring prospective adjustment of antidiabetic medication [12].

Corticosteroids

Concurrent corticosteroid use potentiates sodium and fluid retention, elevating blood pressure and edema risk above what either agent produces alone.

Post-Market Surveillance: What FAERS Adds to Trial Data

Clinical trials of testosterone cypionate have consistently enrolled relatively healthy men, excluding the highest-risk phenotypes by design. FAERS data, despite its well-known limitations (voluntary reporting, uncertain denominator, lack of a control group), provides the only large-scale view of adverse events in real-world populations.

The top five adverse events by report count in FAERS for testosterone cypionate through 2023 are [3]:

1. Erythrocytosis / polycythemia (approximately 2,100 reports)
2. Pulmonary embolism (approximately 1,400 reports)
3. Deep vein thrombosis (approximately 1,200 reports)
4. Testosterone level increased / supratherapeutic (approximately 900 reports)
5. Mood disorder, including aggression (approximately 700 reports)

The disproportionality between erythrocytosis/VTE reports and reports for other adverse events is consistent with mechanistic plausibility and confirms that hematologic monitoring is the highest-yield safety intervention available to prescribers.

Monitoring Protocols That Reduce Serious Adverse Event Risk

The Endocrine Society 2018 guideline recommends the following monitoring schedule, which evidence supports as the minimum standard [6]:

• Before starting: Serum testosterone (morning, fasting), hematocrit, PSA (men over 40), lipid panel, and a validated sleep apnea screening questionnaire (STOP-BANG or equivalent)
• At 3-6 months: Serum testosterone (trough for IM dosing, day-of-injection for weekly dosing), hematocrit, PSA, and symptom review
• Annually thereafter: Repeat the full baseline panel; add BMD measurement at 1-2 years for men with baseline osteopenia

Patients in the moderate-to-high-risk phenotype tiers described above require more frequent monitoring. Men with a baseline hematocrit of 48-50% should have a repeat Hct at 6 weeks, not 3 months.

Stopping Testosterone Cypionate: Adverse Events of Discontinuation

Abrupt discontinuation of testosterone cypionate after prolonged use (greater than 6 months) carries its own adverse event burden. Hypogonadal symptom rebound occurs in virtually all men. More specifically, suppression of the hypothalamic-pituitary-gonadal (HPG) axis may require 3-12 months to recover, with some evidence suggesting permanent impairment after more than 5 years of continuous use.

A 2020 study in the Journal of Clinical Endocrinology and Metabolism found that HPG axis recovery to baseline testosterone levels took a median of 3.8 months after short-course TRT (<12 months) but exceeded 12 months in 26% of men who had used testosterone for more than 3 years [13].

For men who wish to discontinue and preserve or restore fertility, selective estrogen receptor modulators (clomiphene citrate 25-50 mg daily or tamoxifen 20 mg daily) are used off-label to stimulate endogenous LH and FSH secretion during the recovery period.